Evommune amends Jeegar Pravinkumar Patel’s options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel amended two options on November 13, 2026: options for 179,619 and 69,315 shares were deemed canceled and replacements for the same amounts granted. Each replacement lists a $7.63 exercise price. Exercise before the earliest of November 13, 2027, a Change in Control, Patel’s death or Disability, termination by Evommune without Cause, or resignation after a Change in Control for Good Reason requires a premium equal to the original $16 or $26.77 exercise price, respectively. Both awards vest subject to continuous service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to buy) F1, F2, F3 | 179,619 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F1, F2, F3 | 179,619 | -- | -- |
| Disposition | Stock Option (Right to buy) F4, F2, F5 | 69,315 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F4, F2, F5 | 69,315 | -- | -- |
Footnotes (5)
- F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
- F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
- F3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
- F5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Key Terms
Option Repricing financial
Change in Control technical
continuous service technical
Good Reason technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How do EVMN chief scientific officer Jeegar Pravinkumar Patel’s replacement options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.